{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:35:51Z","timestamp":1792992951747,"version":"4.5.0"},"reference-count":50,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.25122\/jml-2025-0148","type":"journal-article","created":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:05:27Z","timestamp":1792991127000},"page":"503-510","source":"Crossref","is-referenced-by-count":0,"title":["Understanding anti-vascular endothelial growth factor medications: chemical properties, costs, and side effects"],"prefix":"10.25122","volume":"19","author":[{"given":"Shaden","family":"Alhazmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"College of Medicine, Taibah University, Medina, Saudi Arabia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Makhdoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Ophthalmology, College of Medicine, Taibah University","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"College of Medicine, Taibah University, Medina, Saudi Arabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlam","family":"Alrehaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"College of Medicine, Taibah University, Medina, Saudi Arabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahaf","family":"Afandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Ophthalmology, Ohud Hospital, Madinah, Saudi Arabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghadi","family":"Aljohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"College of Medicine, Taibah University, Medina, Saudi Arabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Department of Ophthalmology, Ohud Hospital, Madinah, Saudi Arabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10755","reference":[{"issue":"9","key":"ref1","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1172\/JCI126655","article-title":"Roles of HIFs and VEGF in angiogenesis in the retina and brain","volume":"129","author":"Rattner A, Williams J, Nathans J","year":"2019","unstructured":"1. Rattner A, Williams J, Nathans J, Roles of HIFs and VEGF in angiogenesis in the retina and brain, J Clin Invest, 2019;129(9):3807-3820","journal-title":"J Clin Invest"},{"issue":"4","key":"ref2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME","year":"2008","unstructured":"2. Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME, Vascular endothelial growth factor in eye disease, Prog Retin Eye Res, 2008;27(4):331-371","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.phrs.2015.11.003","article-title":"Pathophysiology and pharmacological targets of VEGF in diabetic macular edema","volume":"103","author":"Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R","year":"2016","unstructured":"3. Fogli S, Mogavero S, Egan CG, Del Re M, Danesi R, Pathophysiology and pharmacological targets of VEGF in diabetic macular edema, Pharmacol Res, 2016;103149-157","journal-title":"Pharmacol Res"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12886-020-01554-2","article-title":"Anti-vascular endothelial growth factor in neovascular age-related macular degeneration-a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems","volume":"20","author":"Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P","year":"2020","unstructured":"4. Finger RP, Daien V, Eldem BM, Talks JS, Korobelnik JF, Mitchell P, Anti-vascular endothelial growth factor in neovascular age-related macular degeneration-a systematic review of the impact of anti-VEGF on patient outcomes and healthcare systems, BMC Ophthalmol, 2020;20(1):294","journal-title":"BMC Ophthalmol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"118881","DOI":"10.1016\/j.biopha.2025.118881","article-title":"Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: insights from a systematic review and network meta-analysis","volume":"196","author":"Chen KY, Chan HC, Chan CM","year":"2026","unstructured":"5. Chen KY, Chan HC, Chan CM, Comparative effectiveness and safety landscape of anti-VEGF therapies for neovascular age-related macular degeneration: insights from a systematic review and network meta-analysis, Biomed Pharmacother, 2026;196118881","journal-title":"Biomed Pharmacother"},{"issue":"8","key":"ref6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/pharmaceutics11080365","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration","volume":"11","author":"Garc\u00eda-Quintanilla L, Luaces-Rodr\u00edguez A, Gil-Mart\u00ednez M, Mondelo-Garc\u00eda C, Maro\u00f1as O, Mangas-Sanjuan V","year":"2019","unstructured":"6. Garc\u00eda-Quintanilla L, Luaces-Rodr\u00edguez A, Gil-Mart\u00ednez M, Mondelo-Garc\u00eda C, Maro\u00f1as O, Mangas-Sanjuan V, Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration, Pharmaceutics, 2019;11(8):365","journal-title":"Pharmaceutics"},{"issue":"8","key":"ref7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","article-title":"Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial","volume":"126","author":"Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC","year":"2019","unstructured":"7. Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, Simultaneous inhibition of angiopoietin-2 and vascular endothelial growth factor-A with faricimab in diabetic macular edema: BOULEVARD phase 2 randomized trial, Ophthalmology, 2019;126(8):1155-1170","journal-title":"Ophthalmology"},{"issue":"5","key":"ref8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","article-title":"Predicted biological activity of intravitreal VEGF Trap","volume":"92","author":"Stewart MW, Rosenfeld PJ","year":"2008","unstructured":"8. Stewart MW, Rosenfeld PJ, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol, 2008;92(5):667-668","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"ref9","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara N, Damico L, Shams N, Lowman H, Kim R","year":"2006","unstructured":"9. Ferrara N, Damico L, Shams N, Lowman H, Kim R, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina, 2006;26(8):859-870","journal-title":"Retina"},{"issue":"5","key":"ref10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara N, Hillan KJ, Gerber HP, Novotny W","year":"2004","unstructured":"10. Ferrara N, Hillan KJ, Gerber HP, Novotny W, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 2004;3(5):391-400","journal-title":"Nat Rev Drug Discov"},{"issue":"27","key":"ref11","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group","year":"2004","unstructured":"11. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR, VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group, Pegaptanib for neovascular age-related macular degeneration, N Engl J Med, 2004;351(27):2805-2816","journal-title":"N Engl J Med"},{"issue":"11","key":"ref12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases","volume":"8","author":"Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB","year":"2016","unstructured":"12. Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CMG, Bo Tun SB, Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases, EMBO Mol Med, 2016;8(11):1265-1288","journal-title":"EMBO Mol Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2147\/OPTH.S503060","article-title":"Human factors studies to assess the usability of the faricimab prefilled syringe","volume":"19","author":"Barakat MR, Kwong HM, Marcon G, O\u2019Leary OE, Paris LP, Schneider P","year":"2025","unstructured":"13. Barakat MR, Kwong HM, Marcon G, O\u2019Leary OE, Paris LP, Schneider P, Human factors studies to assess the usability of the faricimab prefilled syringe, Clin Ophthalmol, 2025;19395-406","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"ref14","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cells9081869","article-title":"Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab","volume":"9","author":"Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM","year":"2020","unstructured":"14. Khan M, Aziz AA, Shafi NA, Abbas T, Khanani AM, Targeting angiopoietin in retinal vascular diseases: a literature review and summary of clinical trials involving faricimab, Cells, 2020;9(8):1869","journal-title":"Cells"},{"issue":"2","key":"ref15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","article-title":"Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab","volume":"15","author":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E","year":"2012","unstructured":"15. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, 2012;15(2):171-185","journal-title":"Angiogenesis"},{"issue":"1","key":"ref16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s13554-012-0003-4","article-title":"Aflibercept: a potent vascular endothelial growth factor antagonist for neovascular age-related macular degeneration and other retinal vascular diseases","volume":"2","author":"Sophie R, Akhtar A, Sepah YJ, Ibrahim M, Bittencourt M, Do DV","year":"2012","unstructured":"16. Sophie R, Akhtar A, Sepah YJ, Ibrahim M, Bittencourt M, Do DV, Aflibercept: a potent vascular endothelial growth factor antagonist for neovascular age-related macular degeneration and other retinal vascular diseases, Biol Ther, 2012;2(1):3","journal-title":"Biol Ther"},{"issue":"17","key":"ref17","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M","year":"2002","unstructured":"17. Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci U S A, 2002;99(17):11393-11398","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1177\/8755122515599552","article-title":"Ranibizumab: a review of its use in the treatment of diabetic retinopathy in patients with diabetic macular edema","volume":"32","author":"Akiyode O, Dunkelly-Allen N","year":"2016","unstructured":"18. Akiyode O, Dunkelly-Allen N, Ranibizumab: a review of its use in the treatment of diabetic retinopathy in patients with diabetic macular edema, J Pharm Technol, 2016;32(1):22-28","journal-title":"J Pharm Technol"},{"issue":"8","key":"ref19","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00003495-200767080-00007","article-title":"Ranibizumab","volume":"67","author":"Blick SKA, Keating GM, Wagstaff AJ","year":"2007","unstructured":"19. Blick SKA, Keating GM, Wagstaff AJ, Ranibizumab, Drugs, 2007;67(8):1199-1206discussion 1207-1209","journal-title":"Drugs"},{"issue":"2","key":"ref20","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration","volume":"46","author":"Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V","year":"2005","unstructured":"20. Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V, Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration, Invest Ophthalmol Vis Sci, 2005;46(2):726-733","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"ref21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1006\/jmbi.1999.3192","article-title":"Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen","volume":"293","author":"Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P","year":"1999","unstructured":"21. Chen Y, Wiesmann C, Fuh G, Li B, Christinger HW, McKay P, Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen, J Mol Biol, 1999;293(4):865-881","journal-title":"J Mol Biol"},{"issue":"5","key":"ref22","doi-asserted-by":"publisher","first-page":"e0197670","DOI":"10.1371\/journal.pone.0197670","article-title":"The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration \u2014 a cost-effectiveness analysis from a societal perspective","volume":"13","author":"van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM","year":"2018","unstructured":"22. van Asten F, Michels CTJ, Hoyng CB, van der Wilt GJ, Klevering BJ, Rovers MM, The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration \u2014 a cost-effectiveness analysis from a societal perspective, PLoS One, 2018;13(5):e0197670","journal-title":"PLoS One"},{"issue":"20","key":"ref23","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL","year":"2011","unstructured":"23. CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 2011;364(20):1897-1908","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.2147\/OPTH.S74050","article-title":"Population pharmacokinetics of pegaptanib sodium (Macugen\u00ae) in patients with diabetic macular edema","volume":"9","author":"Basile AS, Hutmacher MM, Kowalski KG, Gandelman KY, Nickens DJ","year":"2015","unstructured":"24. Basile AS, Hutmacher MM, Kowalski KG, Gandelman KY, Nickens DJ, Population pharmacokinetics of pegaptanib sodium (Macugen\u00ae) in patients with diabetic macular edema, Clin Ophthalmol, 2015;9323-335","journal-title":"Clin Ophthalmol"},{"issue":"12","key":"ref25","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R","year":"2014","unstructured":"25. Avery RL, Castellarin AA, Steinle NC, Dhoot DS, Pieramici DJ, See R, Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD, Br J Ophthalmol, 2014;98(12):1636-1641","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"ref26","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S","year":"2020","unstructured":"26. Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial, JAMA Ophthalmol, 2020;138(9):964-972","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"ref27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","article-title":"Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration","volume":"244","author":"Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG","year":"2021","unstructured":"27. Tadayoni R, Sararols L, Weissgerber G, Verma R, Clemens A, Holz FG, Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration, Ophthalmologica, 2021;244(2):93-101","journal-title":"Ophthalmologica"},{"issue":"5","key":"ref28","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study","volume":"123","author":"Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F","year":"2016","unstructured":"28. Holz FG, Dugel PU, Weissgerber G, Hamilton R, Silva R, Bandello F, Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study, Ophthalmology, 2016;123(5):1080-1089","journal-title":"Ophthalmology"},{"issue":"7","key":"ref29","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK","year":"2021","unstructured":"29. Mon\u00e9s J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER, Ophthalmology, 2021;128(7):1050-1059","journal-title":"Ophthalmology"},{"issue":"7","key":"ref30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani KG, Nguyen QD","year":"2013","unstructured":"30. Falavarjani KG, Nguyen QD, Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature, Eye (Lond), 2013;27(7):787-794","journal-title":"Eye (Lond)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma P, Pan X, Liu R, Qu Y, Xie L, Xie J","year":"2022","unstructured":"31. Ma P, Pan X, Liu R, Qu Y, Xie L, Xie J, Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS), Front Pharmacol, 2022;131017889","journal-title":"Front Pharmacol"},{"issue":"2","key":"ref32","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/aos.15242","article-title":"Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies","volume":"101","author":"Baumal CR, S\u00f8rensen TL, Karcher H, Freitas RL, Becher A, Balez S","year":"2023","unstructured":"32. Baumal CR, S\u00f8rensen TL, Karcher H, Freitas RL, Becher A, Balez S, Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies, Acta Ophthalmol, 2023;101(2):123-139","journal-title":"Acta Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"890732","DOI":"10.3389\/fphar.2022.890732","article-title":"The efficacy and safety of brolucizumab for the treatment of nAMD: a systematic review and meta-analysis","volume":"13","author":"Chuan J, Liu L, Feng Y, Wang M, Li G, Lv Q","year":"2022","unstructured":"33. Chuan J, Liu L, Feng Y, Wang M, Li G, Lv Q, The efficacy and safety of brolucizumab for the treatment of nAMD: a systematic review and meta-analysis, Front Pharmacol, 2022;13890732","journal-title":"Front Pharmacol"},{"issue":"10","key":"ref34","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1097\/IAE.0b013e31820f4b4f","article-title":"Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate","volume":"31","author":"Bhatt SS, Stepien KE, Joshi K","year":"2011","unstructured":"34. Bhatt SS, Stepien KE, Joshi K, Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate, Retina, 2011;31(10):2032-2036","journal-title":"Retina"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.21608\/ejomos.2022.148575.1061","article-title":"Safety of intravitreal anti-VEGF injections in diabetic macular edema","volume":"3","author":"Abouelkheir H, Elshafey M, Othman MM, Saber MM, El-Ansarey H, Kamel R","year":"2023","unstructured":"35. Abouelkheir H, Elshafey M, Othman MM, Saber MM, El-Ansarey H, Kamel R, Safety of intravitreal anti-VEGF injections in diabetic macular edema, Egypt J Ophthalmol, 2023;382-92","journal-title":"Egypt J Ophthalmol"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","first-page":"e001702","DOI":"10.1136\/bmjophth-2024-001702","article-title":"Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis","volume":"9","author":"Samac\u00e1-Samac\u00e1 D, Hern\u00e1ndez-Castillo C, Prieto-Pinto L, Rodr\u00edguez F, Sardi C, Ocampo H","year":"2024","unstructured":"36. Samac\u00e1-Samac\u00e1 D, Hern\u00e1ndez-Castillo C, Prieto-Pinto L, Rodr\u00edguez F, Sardi C, Ocampo H, Efficacy and safety of faricimab for neovascular age-related macular degeneration: a systematic review and network meta-analysis, BMJ Open Ophthalmol, 2024;9(1):e001702","journal-title":"BMJ Open Ophthalmol"},{"issue":"9","key":"ref37","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C","year":"2024","unstructured":"37. Tadayoni R, Paris LP, Danzig CJ, Abreu F, Khanani AM, Brittain C, Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials, Ophthalmology, 2024;131(9):950-960","journal-title":"Ophthalmology"},{"issue":"1","key":"ref38","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1038\/s41598-024-52942-3","article-title":"Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis","volume":"14","author":"Yen WT, Wu CS, Yang CH, Chen YH, Lee CH, Hsu CR","year":"2024","unstructured":"38. Yen WT, Wu CS, Yang CH, Chen YH, Lee CH, Hsu CR, Efficacy and safety of intravitreal faricimab for neovascular age-related macular degeneration: a systematic review and meta-analysis, Sci Rep, 2024;14(1):2485","journal-title":"Sci Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"107335","DOI":"10.1016\/j.phrs.2024.107335","article-title":"Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: a systematic review, meta-analysis, and trial sequential analysis","volume":"208","author":"Zhang G, Wen X, Li Y, Sun J, Jia H, Sun X","year":"2024","unstructured":"39. Zhang G, Wen X, Li Y, Sun J, Jia H, Sun X, Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: a systematic review, meta-analysis, and trial sequential analysis, Pharmacol Res, 2024;208107335","journal-title":"Pharmacol Res"},{"issue":"12","key":"ref40","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamaophthalmol.2023.5248","article-title":"Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial","volume":"141","author":"Singh RP, Barakat MR, Ip MS, Wykoff CC, Eichenbaum DA, Joshi S","year":"2023","unstructured":"40. Singh RP, Barakat MR, Ip MS, Wykoff CC, Eichenbaum DA, Joshi S, Efficacy and safety of brolucizumab for diabetic macular edema: the KINGFISHER randomized clinical trial, JAMA Ophthalmol, 2023;141(12):1152-1160","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"ref41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4103\/joco.joco_308_21","article-title":"Efficacy and safety of aflibercept therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"34","author":"Santhakumaran S, Salimi A, Brunetti VC, Galic J","year":"2022","unstructured":"41. Santhakumaran S, Salimi A, Brunetti VC, Galic J, Efficacy and safety of aflibercept therapy for diabetic macular edema: a systematic review and meta-analysis, J Curr Ophthalmol, 2022;34(2):133-147","journal-title":"J Curr Ophthalmol"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/jcm9051522","article-title":"Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies","volume":"9","author":"Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M","year":"2020","unstructured":"42. Plyukhova AA, Budzinskaya MV, Starostin KM, Rejdak R, Bucolo C, Reibaldi M, Comparative safety of bevacizumab, ranibizumab, and aflibercept for treatment of neovascular age-related macular degeneration (AMD): a systematic review and network meta-analysis of direct comparative studies, J Clin Med, 2020;9(5):1522","journal-title":"J Clin Med"},{"issue":"4","key":"ref43","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1007\/s40123-024-00915-0","article-title":"Efficacy, safety, and treatment burden of aflibercept 2 mg and ranibizumab in retinal vein occlusion: a systematic review and meta-analysis","volume":"13","author":"Wu J, He X, Qi F, Zhao Z, Xu Z, Yan H","year":"2024","unstructured":"43. Wu J, He X, Qi F, Zhao Z, Xu Z, Yan H, Efficacy, safety, and treatment burden of aflibercept 2 mg and ranibizumab in retinal vein occlusion: a systematic review and meta-analysis, Ophthalmol Ther, 2024;13(4):1255-1269","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"ref44","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.oret.2018.04.018","article-title":"Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis","volume":"2","author":"Zarbin MA, Francom S, Grzeschik S, Tuomi L, Haskova Z, Macfadden W","year":"2018","unstructured":"44. Zarbin MA, Francom S, Grzeschik S, Tuomi L, Haskova Z, Macfadden W, Systemic safety in ranibizumab-treated patients with neovascular age-related macular degeneration: a patient-level pooled analysis, Ophthalmol Retina, 2018;2(12):1087-1096","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"ref45","doi-asserted-by":"publisher","first-page":"CD011230","DOI":"10.1002\/14651858.CD011230.pub2","article-title":"Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration","volume":"2014","author":"Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U","year":"2014","unstructured":"45. Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration, Cochrane Database Syst Rev, 2014;2014(9):CD011230","journal-title":"Cochrane Database Syst Rev"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ajo.2020.05.029","article-title":"Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration","volume":"218","author":"Brown GC, Brown MM, Rapuano S, Boyer D","year":"2020","unstructured":"46. Brown GC, Brown MM, Rapuano S, Boyer D, Cost-utility analysis of VEGF inhibitors for treating neovascular age-related macular degeneration, Am J Ophthalmol, 2020;218225-241","journal-title":"Am J Ophthalmol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"S111","DOI":"10.1016\/j.jval.2022.09.543","article-title":"EE296 cost-effectiveness of faricimab in patients with neovascular age-related macular degeneration in Canada","volume":"25","author":"B\u00fchrer C, Paulo T, Diles D","year":"2022","unstructured":"47. B\u00fchrer C, Paulo T, Diles D, EE296 cost-effectiveness of faricimab in patients with neovascular age-related macular degeneration in Canada, Value Health, 2022;25(6 Suppl):S111-S112","journal-title":"Value Health"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.36469\/001c.129832","article-title":"Cost-effectiveness and budget impact analysis of the use of faricimab in diabetic macular edema and neovascular age-related macular degeneration in Colombia","volume":"12","author":"Samac\u00e1-Samac\u00e1 D, Robles A, Ocampo H, Rodr\u00edguez FJ, Sardi-Correa C, Prieto-Pinto L","year":"2025","unstructured":"48. Samac\u00e1-Samac\u00e1 D, Robles A, Ocampo H, Rodr\u00edguez FJ, Sardi-Correa C, Prieto-Pinto L, Cost-effectiveness and budget impact analysis of the use of faricimab in diabetic macular edema and neovascular age-related macular degeneration in Colombia, J Health Econ Outcomes Res, 2025;12(1):97-105","journal-title":"J Health Econ Outcomes Res"},{"issue":"6","key":"ref49","doi-asserted-by":"publisher","first-page":"743","DOI":"10.18553\/jmcp.2021.27.6.743","article-title":"Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis","volume":"27","author":"Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC","year":"2021","unstructured":"49. Yu JS, Carlton R, Agashivala N, Hassan T, Wykoff CC, Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis, J Manag Care Spec Pharm, 2021;27(6):743-752","journal-title":"J Manag Care Spec Pharm"},{"issue":"5","key":"ref50","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/ijerph19052548","article-title":"Retrospective analysis of the pharmaco-utilization of VEGF inhibitors and health care costs among patients with wet age-related macular degeneration and other ocular diseases in Italy","volume":"19","author":"Perrone V, Dovizio M, Veronesi C, Citraro R, De Francesco A, Dell\u2019Orco S","year":"2022","unstructured":"50. Perrone V, Dovizio M, Veronesi C, Citraro R, De Francesco A, Dell\u2019Orco S, Retrospective analysis of the pharmaco-utilization of VEGF inhibitors and health care costs among patients with wet age-related macular degeneration and other ocular diseases in Italy, Int J Environ Res Public Health, 2022;19(5):2548","journal-title":"Int J Environ Res Public Health"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/all-issues\/2026\/issue-7-2026\/review-issue-7-2026\/understanding-anti-vascular-endothelial-growth-factor-medications-chemical-properties-costs-and-side-effects\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T05:05:29Z","timestamp":1792991129000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/all-issues\/2026\/issue-7-2026\/review-issue-7-2026\/understanding-anti-vascular-endothelial-growth-factor-medications-chemical-properties-costs-and-side-effects\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["JMedLife-19-503"],"URL":"https:\/\/doi.org\/10.25122\/jml-2025-0148","relation":{},"ISSN":["1844-3117"],"issn-type":[{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}